Publications

JOURNAL ARTICLES

Journal Articles

Jagannath S, Joseph N, Crivera C, Kharat A, Jackson CC, Valluri S, Cost P, Phelps H, Slowik R, Klein T, Smolen L, Yu X, Cohen AD. Component Costs of CAR-T Therapy in Addition to Treatment Acquisition Costs in Patients with Multiple Myeloma. Oncol Ther. 2023 Apr 4. doi: 10.1007/s40487-023-00228-5. Epub ahead of print. PMID: 37014590.

Molife C, Brnabic A, Stefaniak VJ, Belger MA, Gruver K, Chen JV, Souri S, Blumenschein GR Jr. Sintilimab plus chemotherapy for first-line treatment of advanced or metastatic nonsquamous non-small-cell lung cancer: network meta-analysis. Immunotherapy. 2023 Mar;15(4):293-309. doi: 10.2217/imt-2022-0252. Epub 2023 Feb 7. PMID: 36748406.

Smith HT, de Souza AR, Thompson AH, McLaughlin MM, Dever JJ, Myers JA, Chen JV. Cholestatic Pruritus Treatments in Primary Biliary Cholangitis and Primary Sclerosing Cholangitis: A Systematic Literature Review. Dig Dis Sci. 2023 Mar 18. doi: 10.1007/s10620-023-07862-z. Epub ahead of print. PMID: 36933112.

Kennelly M, Wielage R, Shortino D, Thomas E, Mudd PN Jr. Long-term efficacy and safety of vibegron versus mirabegron and anticholinergics for overactive bladder: a systematic review and network meta-analysis. Drugs Context. 2022 Oct 10;11:2022-4-2. doi: 10.7573/dic.2022-4-2. PMID: 36303599; PMCID: PMC9576010.

Chen JV, Klein TM, Nesheim J, Mudd PN Jr. Cost-effectiveness of vibegron for the treatment of overactive bladder in the United States. J Med Econ. 2022 Jan-Dec;25(1):1092-1100. doi: 10.1080/13696998.2022.2115754. PMID: 35993729.

Tew M, Willis M, Asseburg C, Bennett H, Brennan A, Feenstra T, Gahn J, Gray A, Heathcote L, Herman WH, Isaman D, Kuo S, Lamotte M, Leal J, McEwan P, Nilsson A, Palmer AJ, Patel R, Pollard D, Ramos M, Sailer F, Schramm W, Shao H, Shi L, Si L, Smolen HJ, Thomas C, Tran-Duy A, Yang C, Ye W, Yu X, Zhang P, Clarke P. Exploring Structural Uncertainty and Impact of Health State Utility Values on Lifetime Outcomes in Diabetes Economic Simulation Models: Findings from the Ninth Mount Hood Diabetes Quality-of-Life Challenge. Med Decis Making. 2022 Jul;42(5):599-611. doi: 10.1177/0272989X211065479. Epub 2021 Dec 15. PMID: 34911405; PMCID: PMC9329757.

Chen JV, Gahn JC, Nesheim J, Mudd PN Jr. Budget Impact Analysis of Vibegron for the Treatment of Overactive Bladder in the USA. Pharmacoeconomics. 2022 Oct;40(10):979-988. doi: 10.1007/s40273-022-01163-5. Epub 2022 Jul 26. PMID: 35881325; PMCID: PMC9522665.

Boustani M, Doty EG, Garrison LP Jr, Smolen LJ, Belger M, Klein TM, Murphy DR, Burge R, Wall JK, Johnston JA. Assessing the Cost-effectiveness of a Hypothetical Disease-modifying Therapy With Limited Duration for the Treatment of Early Symptomatic Alzheimer Disease. Clin Ther. 2022 Nov;44(11):1449-1462. doi: 10.1016/j.clinthera.2022.09.008. Epub 2022 Oct 7. PMID: 36210219.

Neffen H, Yorgancioglu A, Al-Jahdali H, McLachlan S, Bly C, Martin P, Noibi S. (2021). Is there association and correlation between patient symptom perception and asthma control? A rapid literature review. Chest Journal. October 2021; 160(4):A2398-A2399.

Silberstein SD, Cohen JM, Driessen M, Muresan B, Krasenbaum LJ, Johnston A, Seminerio MJ, Carr K, Akcicek H, Dever J. (2021). Network Meta-analysis on Monthly Migraine Day Reductions With Fremanezumab, Rimegepant, and Atogepant in the Prevention of Episodic Migraine. The Journal of Headache and Pain. 2021 September; 22(Suppl 2):P0471.

Ohsfeldt RL, Choong CK, Mc Collam PL, Abedtash H, Kelton KA, Burge R. Inpatient Hospital Costs for COVID-19 Patients in the United States. Adv Ther. 2021 Nov;38(11):5557-5595. doi: 10.1007/s12325-021-01887-4. Epub 2021 Oct 5. PMID: 34609704; PMCID: PMC8491188.

Kelton K, Klein T, Murphy D, Belger M, Hille E, McCollam PL, Spiro T, Burge R. Cost-Effectiveness of Combination of Baricitinib and Remdesivir in Hospitalized Patients with COVID-19 in the United States: A Modelling Study. Adv Ther. 2022 Jan;39(1):562-582. doi: 10.1007/s12325-021-01982-6. Epub 2021 Nov 22. PMID: 34807369; PMCID: PMC8606629.

Ohsfeldt R, Kelton K, Klein T, Belger M, Mc Collam PL, Spiro T, Burge R, Ahuja N. Cost-Effectiveness of Baricitinib Compared With Standard of Care: A Modeling Study in Hospitalized Patients With COVID-19 in the United States. Clin Ther. 2021 Nov;43(11):1877-1893.e4. doi: 10.1016/j.clinthera.2021.09.016. Epub 2021 Oct 4. PMID: 34732289; PMCID: PMC8487786.

Si L, Willis MS, Asseburg C, Nilsson A, Tew M, Clarke PM, Lamotte M, Ramos M, Shao H, Shi L, Zhang P, McEwan P, Ye W, Herman WH, Kuo S, Isaman DJ, Schramm W, Sailer F, Brennan A, Pollard D, Smolen HJ, Leal J, Gray A, Patel R, Feenstra T, Palmer AJ. Evaluating the Ability of Economic Models of Diabetes to Simulate New Cardiovascular Outcomes Trials: A Report on the Ninth Mount Hood Diabetes Challenge. Value Health. 2020 Sep;23(9):1163-1170. doi: 10.1016/j.jval.2020.04.1832. Epub 2020 Aug 6. PMID: 32940234.

Urowitz MB, Ohsfeldt RL, Wielage RC, Dever JJ, Zakerifar M, Asukai Y, Ramachandran S, Joshi AV. Comparative analysis of long-term organ damage in patients with systemic lupus erythematosus using belimumab versus standard therapy: a post hoc longitudinal study. Lupus Sci Med. 2020 Oct;7(1):e000412. doi: 10.1136/lupus-2020-000412. PMID: 33051264; PMCID: PMC7555104.

Urowitz MB, Ohsfeldt RL, Wielage RC, Kelton KA, Asukai Y, Ramachandran S. Organ damage in patients treated with belimumab versus standard of care: a propensity score-matched comparative analysis. Ann Rheum Dis. 2019 Mar;78(3):372-379. doi: 10.1136/annrheumdis-2018-214043. Epub 2019 Jan 4. PMID: 30610066; PMCID: PMC6390027.

Bly CA, Molife C, Brown J, Tawney MK, Carter GC, Cinfio FN, Klein RW. The Budget Impact of Including Necitumumab on the Formulary for First-Line Treatment of Metastatic Squamous Non-Small Cell Lung Cancer: U.S. Commercial Payer and Medicare Perspectives. J Manag Care Spec Pharm. 2018 Jun;24(6):534-543. doi:10.18553/jmcp.2018.24.6.534. PubMed PMID: 29799326.

Chen S, Golam S, Myers J, Bly C, Smolen H, Xu X. Systematic literature review of the clinical, humanistic, and economic burden associated with asthma uncontrolled by GINA Steps 4 or 5 treatment. Curr Med Res Opin. 2018 Jul 26:1-33. doi: 10.1080/03007995.2018.1505352. [Epub ahead of print] PubMed PMID: 30047292.

Palmer AJ, Si L, Tew M, Hua X, Willis MS, Asseburg C, McEwan P, Leal J, Gray A, Foos V, Lamotte M, Feenstra T, O’Connor PJ, Brandle M, Smolen HJ, Gahn JC, Valentine WJ, Pollock RF, Breeze P, Brennan A, Pollard D, Ye W, Herman WH, Isaman DJ, Kuo S, Laiteerapong N, Tran-Duy A, Clarke PM. Computer Modeling of Diabetes and Its Transparency: A Report on the Eighth Mount Hood Challenge. Value Health. 2018 Jun;21(6):724-731. doi: 10.1016/j.jval.2018.02.002. Epub 2018 Apr 9. PubMed PMID: 29909878.

Klein RW, Kabadi S, Cinfio FN, Bly CA, Taylor DC, Szymanski KA. Budget impact of adding lesinurad for second-line treatment of gout: a US health plan perspective. J Comp Eff Res. 2018 May 24. doi: 10.2217/cer-2017-0103. [Epub ahead of print] PubMed PMID: 29792516.

Kelton KA, Perk S, Loveland S, Perez-Nieves M, Fu H, Peng X. Economic outcomes with the conversion of insulin delivery methods in hospitals. J Med Econ. 2017 May;20(5):533-540. doi: 10.1080/13696998.2017.1288126. Epub 2017 Feb 16.

Campbell NL, Perkins AJ, Bradt P, Perk S, Wielage RC, Boustani MA, Ng DB. Association of Anticholinergic Burden with Cognitive Impairment and Health Care Utilization Among a Diverse Ambulatory Older Adult Population. Pharmacotherapy. 2016 Nov;36(11):1123-1131. doi: 10.1002/phar.1843. Epub 2016 Nov 5.

Perk S, Wielage RC, Campbell NL, Klein TM, Perkins A, Posta LM, Yuran T, Klein RW, Ng DB. Estimated Budget Impact of Increased Use of Mirabegron, A Novel Treatment for Overactive Bladder. J Manag Care Spec Pharm. 2016 Sep;22(9):1072-84.

Wielage RC, Perk S, Campbell NL, Klein TM, Posta LM, Yuran T, Klein RW, Ng DB. Mirabegron for the treatment of overactive bladder: cost-effectiveness from US commercial health-plan and Medicare Advantage perspectives. J Med Econ. 2016 Dec;19(12):1135-1143. Epub 2016 Jul 4.

Hess LM, Cinfio FN, Wetmore S, Churchill C, Fausel C, Ale-Ali A, Gelwicks S, Bly CA, Perk S, Klein RW. Enhancing the Budget Impact Model for Institutional Use: A Tool with Practical Applications for the Hospital Oncology Pharmacy. Hosp Pharm. 2016 Jun;51(6):452-60.

Smolen LJ, Gahn JC, Mitri G, Shiozawa A. The Budget Impact of Increased Use of Febuxostat in the Management of Gout: A US Health Plan Managed Care Pharmacy and Medical Costs Perspective. Clin Ther. 2016 Jul;38(7):1710-25. doi:10.1016/j.clinthera.2016.05.007. Epub 2016 Jun 3.

Curtis BH, Curtis S, Murphy DR, Gahn JC, Perk S, Smolen HJ, Murray J, Numapau N, Bonner JS, Liu R, Johnson J, Glass LC. Evaluation of a patient self-directed mealtime insulin titration algorithm: a US payer perspective. J Med Econ. 2016 Jun;19(6):549-56. doi: 10.3111/13696998.2016.1141098. Epub 2016 Feb 1.

Smolen LJ, Gahn JC, Mitri G, Shiozawa A. Febuxostat in the management of gout: a cost-effectiveness analysis. J Med Econ. 2016;19(3):265-76. doi: 10.3111/13696998.2015.1116990. Epub 2015 Nov 23.

Eby E, Smolen L, Pitts A, Krueger LA, Grimm D. Economic Impact of Converting from Pen and 10-mL Vial to 3-mL Vial for Insulin Delivery in a Hospital Setting. Hosp Pharm. 2014 Dec;49(11):1033-8. doi: 10.1310/hjp4911-1033.

Eby EL, Smolen LJ, Pitts AC, Krueger LA, Andrews JS. Comparison of vials and prefilled pens of a rapid-acting insulin analog on pharmacy budgets in a long-term care setting. Consult Pharm. 2014 Dec;29(12):813-22. doi: 10.4140/TCP.n.2014.813. PMID: 25521657.

Kim BR, Burge R, Klein TM, Smolen LJ. Outcomes in Severe Osteoporotic Women in Korea Using Sequential Treatment. Value Health. 2014 Nov;17(7):A771. doi: 10.1016/j.jval.2014.08.317. Epub 2014 Oct 26.

Smolen HJMurphy DRGahn JCYu X, Curtis BH. The evaluation of clinical and cost outcomes associated with earlier initiation of insulin in patients with type 2 diabetes mellitus. J Manag Care Spec Pharm 2014;20(9):968-984.

Myers JWielage RC, Han B, Price K, Gahn J, Paget MA, Happich M. The efficacy of duloxetine, non-steroidal anti-inflammatory drugs, and opioids in osteoarthritis: a systematic literature review and meta-analysis. BMC Musculoskeletal Disorders 2014;15(1):76.

Hess LM, Carter G, Smolen L, Bowman L, von Hohnhorst P, Seagle C. Re: Cost-effectiveness analysis of screening for KRAS and BRAF mutations in metastatic colorectal cancer. J Natl Cancer Inst. 2014 Feb;106(2):djt370. doi: 10.1093/jnci/djt370. Epub 2013 Dec 31. PubMed PMID: 24381069.

Li Y, Zhu M, Klein R, Kong N. Using a partially observable Markov chain model to assess colonoscopy screening strategies– A cohort study. European Journal of Operational Research 2014;238(1):313-326.

Smolen LJKlein TMBly CA, Ryan KJ. Cost-effectiveness of live attenuated versus inactivated influenza vaccine among children. The American Journal of Pharmacy Benefits 2014;6(4):171-182.

Wielage RCPatel A, Bansal M, Lee S, Klein R, Happich M. The cost effectiveness of duloxetine for osteoarthritis: a Quebec societal perspective. Arthritis Care and Research 2014;66(5):702-8.

Furiak N, Duhig AM, Myers JPitts A, Hass S, Klein R. Economic considerations of cognition and functional outcomes in patients with schizophrenia: a systematic literature review. Schizophrenia Research: Cognition 2014;1(1):e27-e33.

Wielage RC, Bansal M, Andrews JS, Wohlreich MM, Klein RW, Happich M. The cost-effectiveness of duloxetine in chronic low back pain: a US private payer perspective. Value Health 2013 Mar-Apr;16(2):334-44.

Wielage RCMyers JAKlein RW, Happich M. Cost-effectiveness analyses of osteoarthritis oral therapies: a systematic review. Applied Health Economics and Health Policy 2013. Dec;11(6):593-618.

Wielage RC, Bansal M, Andrews JS, Wohlreich MM, Klein RW, Happich M. The cost-effectiveness of duloxetine in chronic low back pain: a US private payer perspective-author response to letter to the editor. Value Health. 2013 Dec;16(8):1173-4. doi: 10.1016/j.jval.2013.09.005. PubMed PMID: 24326173.

Wielage RC, Bansal M, Andrews JS, Klein RW, Happich M. Cost-utility analysis of duloxetine in osteoarthritis: a US private payer perspective. Applied Health Economics and Health Policy 2013 Jun;11(3):219-36.

Wielage R, Bansal M, Wilson K, Klein R, Happich M. The cost-effectiveness of duloxetine in chronic low back pain; a Quebec societal perspective. Spine 2013 May 15;38(11):936-46.

Murphy DRKlein RWSmolen LJKlein TM, Roberts SD. Using common random numbers in healthcare cost-effectiveness simulation modeling. Health Services Research 2013; 48(4):1508-25.

Lee LJ, Smolen LJKlein TM, Foster SA, Whiteman D, Jorgenson JA, Hultgren S. Budget impact analysis of insulin therapies and associated delivery systems. Am J Health Syst Pharm 2012; 69(11):958-65.

Gandhi SK, Jensen MM, Fox KM, Smolen L, Olsson AG, Paulson T. Cost-effectiveness of rosuvastatin in comparison with generic atorvastatin and simvastatin in a Swedish population at high risk of cardiovascular events. Clinicoecon Outcomes Res 2012; 4:1-11. http://www.dovepress.com/cost-effectiveness-of-rosuvastatin-in-comparison-with-generic-atorvast-peer-reviewed-article-CEOR

Furiak NMGahn JCKlein RW, Camper SB, Summers KH. Estimated economic benefits from low-frequency administration of atypical antipsychotics in treatment of schizophrenia: a decision model. Ann Gen Psychiatry 2012;11(1):29. http://www.annals-general-psychiatry.com/content/11/1/29

Murphy DRSmolen LJKlein TMKlein RW. The cost effectiveness of teriparatide as a first line treatment for glucocorticoid-induced and postmenopausal osteoporosis patients in Sweden. BMC Musculoskeletal Disorders 2012;13:213. http://www.biomedcentral.com/1471-2474/13/213

Ascher-Svanum H, Furiak NM, Lawson AH, Klein TMSmolen LJ, Conley RR, Culler SD. Cost-effectiveness of several atypical antipsychotics in orally disintegrating tablets compared with standard oral tablets in the treatment of schizophrenia in the United States. J Med Econ 2012;15(3):531-47.

Furiak NM, Kahle-Wrobleski K, Callahan C, Klein TMKlein RW, Siemers ER. Screening and treatment for Alzheimer’s disease: Predicting population-level outcomes. Alzheimer’s & Dementia 2012;8:31-38.

Kessler WR, Imperiale TF, Klein RWWielage RC, Rex DK. A quantitative assessment of the risks and cost savings of forgoing histologic examination of diminutive polyps. Endoscopy 2011;43:683-91. [Epub May 27 2011].

Furiak NM, Ascher-Svanum H, Klein RWSmolen LJ, Lawson AH, Montgomery W, Conley RR. Cost-effectiveness of olanzapine long-acting injection in the treatment of patients with schizophrenia in the United States: a micro-simulation economic decision model. Current Med Res & Opin. 2011;27(4):713-30.

Yaesoubi R, Roberts SD, Klein RW. A modification of Cheng’s method: an alternative factor screening method for stochastic simulation models. 2010 Winter Simulation Conference Proceedings, IEEE, Piscataway, NJ. 2010:1034-47.

Ohsfeldt RL, Gandhi SK, Smolen LJ, Jensen MM, Fox KM, Gold A, Hsia J. Cost effectiveness of rosuvastatin in patients at risk of cardiovascular disease based on findings from the JUPITER trial. J Med Econ. 2010 Sep;13(3):428-37.

Klein RWielage R, Muehlenbein C, Liepa AM, Babineaux S, Lawson A, Schwartzberg L. Cost-effectiveness of pemetrexed as first-line maintenance therapy for advanced nonsquamous non-small cell lung cancer. J Thorac Oncol. 2010 Aug;5(8):1263-72.

Furiak NMKlein RW, Kahle-Wrobleski K, Siemers ER, Sarpong E, Klein TM. Modeling screening, prevention, and delaying of Alzheimer’s disease: an early-stage decision analytic model. BMC Med Inform Decis Mak. 2010 Apr 30;10:24.

Klein R, Muehlenbein C, Liepa AM, Babineaux S, Wielage R, Schwartzberg L. Cost-effectiveness of pemetrexed plus cisplatin as first-line therapy for advanced nonsquamous non-small cell lung cancer. J Thorac Oncol. 2009 Nov;4(11):1404-14.

Krilov LR, Palazzi DL, Fernandes AW, Klein RW, Mahadevia PJ. Prevalence of respiratory syncytial virus (RSV) risk factors and cost implications of immunoprophylaxis to infants 32 to 35 weeks gestation for health plans in the United States. Value Health 2010;13:77-86. First published online 24 Aug 2009.

Furiak NM, Ascher-Svanum H, Klein RWSmolen LJ, Lawson AH, Conley RR, Culler SD. Cost-effectiveness model comparing olanzapine and other oral atypical antipsychotics in the treatment of schizophrenia in the United States. Cost Eff Resour Alloc. 2009 Apr 7;7:4.

Haas DM, Imperiale TF, Kirkpatrick PR, Klein RW, Zollinger TW, Golichowski AM. Tocolytic therapy: a meta-analysis and decision analysis. Obstetrics & Gynecology 2009;113(3):585-94.

Tafazzoli A, Roberts S, Ness R, Klein R, Dittus R. Probabilistic cost-effectiveness comparison of screening strategies for colorectal cancer. ACM Transactions on Modeling and Computer Simulation 2009;19(2):1-29.

Ascher-Svanum H, Zhu B, Faries DE, Furiak NM, Montgomery W. Medication adherence levels and differential use of mental-health services in the treatment of schizophrenia. BMC Res Notes 2009 Jan 12;2:6.

Roberts S, Wang L, Klein R, Ness R, Dittus R. Development of a simulation model of colorectal cancer. ACM Transactions on Modeling and Computer Simulation 2008;18(1):1-30.

Smolen HJ, Cohen DJ, Samsa GP, Toole JF, Klein RWFuriak NM, Lorell BH. Development, validation, and application of a microsimulation model to predict stroke and mortality in medically-managed asymptomatic patients with significant carotid artery stenosis. Value Health. 2007;10(6):489-97.

Imperiale TF, Klein RW, Chalasani N. A Cost-effectiveness analysis of variceal ligation vs. beta-blockers for primary prevention of variceal bleeding. Hepatology 2007;45(4):870-8.

Meadows ES, Klein R, Rousculp MD, Smolen L, Ohsfeldt RL, Johnston JA. Cost-effectiveness of preventative therapies for postmenopausal women with osteopenia. BMC Women’s Health 2007;7:6. http://www.biomedcentral.com/content/pdf/1472-6874-7-6.pdf

Ness RM, Klein RW, Dittus RS. Appendix G The Vanderbilt Colorectal Cancer Model. In Economic Models of Colorectal Cancer Screening in Average-Risk Adults: Workshop Summary. Pignone M, Russell L, Wagner J, eds. Washington DC, National Academies Press 2005. Available at: 
http://www.iom.edu/CMS/3798/15652/25197.aspx.

Ohsfeldt RL, Kreder KJ, Klein RW, Chrischilles EA. Cost-effectiveness of tamsulosin, doxazosin, and terazosin in the treatment of benign prostatic hyperplasia. J Manag Care Pharm. 2004;10(5):412-22.

Imperiale TF, Chalasani N, Klein RW. Measuring the hemodynamic response to primary pharmacoprophylaxis of variceal bleeding: a cost-effectiveness analysis. Am J Gastroenterol.2003;98(12):2742-50.

Ness RM, Holmes A, Klein R, Dittus R. Cost-utility of one-time colonoscopic screening for colorectal cancer at various ages. Am J Gastroenterol. 2000;95(7):1800-11.

Ness RM, Holmes A, Klein R, Dittus R. Utility valuations for outcome states of colorectal cancer. Am J Gastroenterol. 1999,94(7):1650-7.

 

CONFERENCE PRESENTATIONS

Abstract and Presentations

Price GL, Cinfio FN, Martin PA, Vitko AS, Boye ME, DeLuca A., Bly CA, Manion C, & Brown J. (2022). HSR22-162: Budget Impact Analysis of Abemaciclib in Combination With Endocrine Therapy (ET) in Hormone Receptor-Positive (HR+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-), Node-Positive Early Breast Cancer (EBC) at High Risk of Recurrence and Ki-67 Score ≥20%, Journal of the National Comprehensive Cancer Network, 20(3.5), HSR22-162-HSR22-162. Retrieved Mar 21, 2023, from https://jnccn.org/view/journals/jnccn/20/3.5/article-pHSR22-162.xml

Martin P, Zhang S, Johnson A, & Ohsfeldt R. (2022). Costs of breast cancer recurrence after initial treatment for high risk early breast cancer using SEER-Medicare linked data. San Antonio Breast Cancer Symposium 2022.

Smolen H. (2022). Non-Glycemic Benefits from the Use of SGLT2’s in Type 2 Diabetes: An Exploratory Analysis. Presentation at Mt. Hood 2022 Conference. https://www.mthooddiabeteschallenge.com/abstracts.

Jagannath S, Joseph N, Crivera C, Jackson CC, Valluri S, Cost P, Phelps H, Slowik R, Klein TM, Smolen L, Yu X, Cohen A. (2022). CAR-T Treatment Costs Beyond Therapy Acquisition Costs in Multiple Myeloma Patients. Value in Health 25 (7): S348. (Poster EE70 at ISPOR 27th Annual International Meeting, Washington DC, May 15-18, 2022.)

Boustani M, Doty EG, Garrison LP Jr, Smolen LJ, Belger M, Klein TM, Murphy DR, Burge R, Johnston JA. (2022). Impact of Treatment Duration on the Potential Cost-Effectiveness of Disease-Modifying Therapies for the Treatment of Early Symptomatic Alzheimer’s Disease. Value in Health 25 (7): S385. (Poster EE263 at ISPOR 27th Annual International Meeting, Washington DC, May 15-18, 2022.)

Smolen H, Johnston A, Smolen L, Yih Y. (2021). EPH120 Comparing the Effectiveness and Cost-Effectiveness of SARS-COV-2 Screening Strategies Using Rapid Antigen Tests in a Residential College Campus. Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research. 2022 Jun;25(7):S456-S457. PMCID: PMC9232802.

Chen JV, Klein TM, Mudd PN Jr. (2021). Cost-effectiveness of vibegron for the treatment of overactive bladder in the United States. Value in Health 24 (6): S235. (Poster PUK6 at ISPOR 26th Annual International Meeting, Virtual May 17-20, 2021.)

van Boven J, Hill T, Ariely R, Smolen L, Klein T, Muresan B, Herrera E. (2021). Budget Impact of the Use of Digital Inhalers in Asthma Treatment in the US. J Am Coll Clin Pharm. 4:1190–1256. (Poster at ACCP Virtual Poster Symposium, May 25–26, 2021)

Yu X. (2020). Using the Treatment Transition Model to Estimate the Long-term Outcomes after COVID-19 Infection on Type 2 Diabetes Patients. Presentation at Mt. Hood 2020 Conference.

Smolen, H. (2019). PCV120 A statistical comparison of logistic regression versus machine learning tree-based classification methods in predicting coronary heart disease using real-world patient-level data. Value in Health 22: S563-S564. (Poster PCV120 at ISPOR 24th Annual International Meeting, New Orleans, LA, May 17-20, 2019.)

Smolen H. (2018). Validation of clinical outcomes from a type 2 diabetes pharmacoeconomic model using real world us electronic health record data: initial results and insights. Presentation at Mt. Hood 2018 Conference.

Pérez-Ruiz F, So A, Kandaswamy P, Karra R, Kelton K, Perk S, et al. (2018). Estimating health-related quality of life for gout patients: a post-hoc analysis of utilities from the CLEAR trials. Ann Rheum Dis. 2018;77(Suppl):A132. doi: 10.1136/annrheumdis-2018-eular.6822. Oral presentation OP0162-HPR at EULAR 2018, Amsterdam, Netherlands.

Palmer AJ, Si L, Tew M, Hua X, Willis MS, Asseburg C, McEwan P, Leal J, Gray A, Foos V, Lamotte M, Feenstra T, O’Connor PJ, Brandle M, Smolen HJ, Gahn JC, Valentine WJ, Pollock RF, Breeze P, Brennan A, Pollard D, Ye W, Herman WH, Isaman DJ, Kuo S, Laiteerapong N, Tran-Duy A, Clarke PM. (2018). Computer Modeling of Diabetes and Its Transparency: A Report on the Eighth Mount Hood Challenge. Value Health. 2018 Jun;21(6):724-731. doi: 10.1016/j.jval.2018.02.002. Epub 2018 Apr 9. PMID: 29909878; PMCID: PMC6659402.

Urowitz M, Ohsfeldt RL, Wielage R, Kelton KA, Asukai Y, Ramachandran S. (2017). A Propensity Score-Matched Study of Organ Damage in Patients with Systemic Lupus Erythematosus from the BLISS Long-Term Extension Trials Versus the Toronto Lupus Cohort: A Post Hoc Longitudinal Analysis [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/a-propensity-score-matched-study-of-organ-damage-in-patients-with-systemic-lupus-erythematosus-from-the-bliss-long-term-extension-trials-versus-the-toronto-lupus-cohort-a-post-hoc-longitudinal-analys/.

Murphy DR, Yu X, Fournier M, Klein TM, Fan T, Perk S, Preblick R, Zhou FL. (2017). Cost-Effectiveness of Insulin Glargine 300 units/mL (Gla-300) vs. Insulin Degludec 100 units/mL (IDeg) in T2D,  2017, American Diabetes Association – 77th Scientific Sessions (June 9-13, 2017 – San Diego, California, USA). Drugs Today (Barc). Jul;53(7):405-413. doi: 10.1358/dot.2017.53.7.2669148. PMID: 28837185

Smolen H. (2016). Estimating the cost effectiveness of a patient-directed mealtime insulin titration algorithm. Presentation at Mt. Hood 2016 Conference.

Dalal MR, Feliciano J, Kelton K, Klein T, Murphy D. (2016). Translating Trial-Based Efficacy and Safety into Cost comparison for New Insulin Glargine 300 U/m (Gla-300). 2016, Meeting Abstracts – Annual Meeting 2016, J Managed Care Spec Pharm., Apr;22(4 Suppl):1-132. doi: 10.18553/jmcp.2016.22.4.S1. PMID: 27023780.

Kelton K. (2015). Long-Term Decrease In Gout Flare Rates Associated With Effective Urate Lowering Therapy. Value in Health. 2015 May 1;18(3):A155. doi: 10.1016/j.jval.2015.03.902. Poster presentation PMS17 at ISPOR 2015, Philadelphia, PA, USA.

Kelton K, Loveland S, Perez-Nieves M, Fu H, Peng X. (2015). Economic impact of switching from individual patient supply of 3 mL pens of insulin aspart to floor stock of 3 mL vials of insulin lispro. In: ASHP 2015 Midyear Meeting Professional Poster Abstracts [Internet]. New Orleans, LA; 2015. p. [4-136]. Available from: http://www.ashpmedia.org/mcm15/docs/OPD-Professional-Poster-Abstracts-2015.pdf

Smolen HJ, Yuan M, Hawthorne ME, Wang Q, Kelton K. (2015). Development, validation, and analysis of a linear regression model predicting child’s birthweight from mother’s race, education level, smoking status, and gestation age. Value in Health. 18. A105. 10.1016/j.jval.2015.03.616. (Poster at ISPOR 20th Annual International Meeting, Philadelphia, PA, May 2015.)

Perk S, Murphy DR, Gahn JC, Yu X, Smolen HJ. (2015). PDB42. Estimating Clinical and Economic Outcomes Following a Diabetes-Related vascular Complication. Value in Health. 18. A59-A60. 10.1016/j.jval.2015.03.349. (Poster PDB42 at ISPOR 20th Annual International Meeting, Philadelphia, PA, May 2015.)

Numapau NO, Murphy DR, Curtis B, Gahn JC, Curtis S, Perk S, Yu X, Smolen HJ. (2015). PDB35. modeling the long term economic benefits of a patient-adjusted mealtime insulin titration algorithm among patients with type 2 diabetes in the United States. Value in Health. 18. A58-A59. 10.1016/j.jval.2015.03.342. (Poster PDB35 at ISPOR 20th Annual International Meeting, Philadelphia, PA, May 2015.)

Smolen HJ, Yu X. (2015). PDB6. Using a treatment transition model to evaluate the effects of neglecting hba1c drift in oral anti-diabetic drugs for type 2 diabetes. Value in Health. 18. A53. 10.1016/j.jval.2015.03.313. (Poster PDB6 at ISPOR 20th Annual International Meeting, Philadelphia, PA, May 2015.)

Smolen HJ, Yu X. (2015). PDB6. Using a treatment transition model to Evaluate the Effects of Neglecting Hba1c Drift In oral anti-diabetic Drugs for Type 2 Diabetes. Value in Health. 18. A53. 10.1016/j.jval.2015.03.313. (Poster PDB6 at ISPOR 20th Annual International Meeting, Philadelphia, PA, May 2015.)

Smolen, H.J. & Yu, X. (2015). PDB6. Using a treatment transition model to Evaluate the Effects of Neglecting Hba1c Drift In oral anti-diabetic Drugs for Type 2 Diabetes. Value in Health. 18. A53. 10.1016/j.jval.2015.03.313.

Vivas-Valencia C, Kong N, Imperiale T, Klein R, Tham W. Development of a progressive calibration procedure for model-based cost-effectiveness studies on individualized colorectal cancer screening program. (Oral Presentation WB39-1 at INFORMS Annual Meeting, San Francisco, CA, Nov. 12 2014)

Smolen HJ. Development of an influenza outbreak forecasting model using time series analysis methods. (Poster PRM 102 at ISPOR 17th Annual European Congress, Amsterdam, The Netherlands, Nov, 11, 2014)

Kong N, Imperiale T, Klein R, Vivas-Valencia C. A simulation-based cost-effectiveness study on age and gender-specific CRC screening strategies. (Oral Presentation SD41-1 at INFORMS Annual Meeting, San Francisco, CA, Nov. 9 2014)

Vivas-Valencia C, Kong N, Klein R, Tham W, Imperiale T. A progressive calibration procedure for individualized colorectal cancer screening study. (Oral Presentation TRA-2-4 at the 36th Annual Meeting of the Society for Medical Decision Making, Miami, FL, Oct. 20 2014)

Klein R, Ng D, Perk S, Wielage R, Klein T, Yuran T, Berner T. Economic and clinical impact of switching from antimuscarinics to Mirabegron for the treatment of overactive bladder. (Poster Presentation at the 36th Annual Meeting of the Society for Medical Decision Making, Miami, FL, Oct. 22 2014)

Smolen L, Wielage R, Gahn J, Gaith M, Shiozawa A. The budgetary impact of Febuxostat in the management of patients with gout. (Poster Presentation 2014 AMCP Educational Conference, Tampa, FL, April 1-4 2014)

Smolen L, Wielage R, Gahn J, Gaith M, Shiozawa A. The cost effectiveness of Febuxostat in the management of patients with gout. (Poster Presentation 2014 AMCP Educational Conference, Tampa, FL, April 1-4 2014)

Myers J, Duhig A, Pitts A, Klein RW, Harvey P. Performance on the UCSD performance-based skills assessment (UPSA) and real-world outcomes in severe mental illness: a systematic review of the literature. (Poster Presentation 4th Biennial Schizophrenia International Research Society Conference, Florence, Italy, April 5-9 2014)

Flynn JA, Burge R, Nojiri S, Klein TM, Smolen LJ. Simulation study of the clinical impact of Forteo (teriparatide [rDNA origin] injection) use for two years by postmenopausal osteoporosis (PMO) patients in Japan. 2013 Sep. (Poster Presentation AFOS 2013 Conference, Seoul, Korea, September 6-8, 2013)

Furiak N, Klein RW, Gahn JC, Camper SB, Summers K. Use of a decision tree model to estimate the economic benefits of reducing schizophrenia illness relapse. Value Health 2013 May;16(3):A62-3. (Poster PMH43 ISPOR 18th Annual International Meeting, New Orleans LA, May 20 2013)

Ariely R, Klein R, Gahn JC, Tham WK, Cohen D, Bell C, Tynan A. A model framework evaluating factors affecting the value of treatment one year following an acute coronary syndrome event. Value Health 2013 May;16(3):A288. (Poster PCV91 ISPOR 18th Annual International Meeting, New Orleans LA, May 22 2013)

Smolen H. (2013). MO2. Reanalyzing carotid artery stenosis treatment clinical trial results from a bayesian perspective. Value in Health: the journal of the International Society for Pharmacoeconomics and Outcomes Research. 16. A7-8. 10.1016/j.jval.2013.03.045. (Podium Presentation MO2 ISPOR 18th Annual International Meeting, New Orleans LA, May 2013) 

Ariely R, Klein R, Tham W, Bell C, Smolen L, Tynan A. Identifying and adapting a prognostic risk equation for relevant subppulations in a pharmacoeconomic model of major adverse cardiovascular event prevention. (Poster #176, American Heart Association-Quality of Care and Outcomes Research 2013, Baltimore, MD, May 16 2013)

Furiak N, Duhag A, Myers JA, Hass S, Klein RW, Pitts AC. The economic burden of disease associated with cognitive deficits in patients in schizophrenia. (ID 1517855 14th International Congress on Schizophrenia Research, Orlando, Florida, April 25, 2013)

Wielage R, Samsa G, Klein T, Happich M. A maximum likelihood simulation technique for estimating adverse event rates from published trials. Value in Health 2012;15(7): A487 (Poster PRM145, ISPOR 15th Annual European Congress, Berlin, Germany, Nov 6, 2012)

Myers JA, Klein RW, Han X, Al Haddad M, Smolen, HJ. Evaluating strategies for using DNA testing to identify mucinous pancreatic cysts. Value in Health 2012;15(7): A352-A353. (Poster PMD44 ISPOR 15th Annual European Congress, Berlin, Germany, Nov 5, 2012)

Myers JA, Wielage RC, Han B, Price K, Gahn J, Paget M, Happich M. The efficacy of duloxetine, non-steroidal anti-inflammatory drugs, and opioids in osteoarthritis: A meta-analysis. Value in Health 2012;15(4): A33. (Poster PMS2, ISPOR 17th Annual International Meeting, Washington, DC, June 5, 2012)

Smolen LJ, Klein TM, Voelker JR, Sierra-johnson J, Boye ME. Economic Benefits of Slowing Progress to End Stage Renal Disease (ESRD) in Patients with Diabetes-Related Chronic Kidney Disease (DKD), Compared with Standard of Care (SOC). Value in Health 2012;15(4): A155.

Furiak NM, Bansal M, Gahn JC, Klein RW, Smolen HJ. Validation of a Diabetes Modeling Framework. Value in Health 2012;15(4): A173. (Poster PDB18 ISPOR 17th Annual International Meeting, Washington, DC, June 5, 2012)

Furiak N, Bansal M. Quantifying cost outcomes differentiated by gender and age in the treatment of migraine headache using step and stratified care. Value in Health 2011;14:A206. (Poster PND22 ISPOR 16th Annual International Meeting, Baltimore, Maryland, May 25, 2011)

Furiak N, Bansal M, Gahn JC, Smolen H. Beta-verification of a diabetes modeling framework against published cohort. Value in Health 2011;14:A104. (Poster PDB74 ISPOR 16th Annual International Meeting, Baltimore, Maryland, May 24, 2011)

Smolen HJ, Myers JA, Smolen LJ. Cost-effectiveness modeling in osteoporosis: a systematic literature review and overview. Value in Health 2011;14:A127-A128. (Poster PMS26 ISPOR 16th Annual International Meeting, Baltimore, Maryland, May 24, 2011)

Furiak N. Therapy persistence with disease-modifying AD therapy-Impact on NNT and AD-free years in an asymptomatic population. (Podium presentation at the opening plenary session of the Neurodegenerative Diseases: Biology & Therapeutics Meeting, December 4, 2010, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY.)

Smolen H. An introduction to discrete event simulation and other healthcare modeling techniques. (Workshop presentation at the 8th Conference of the Polish Pharmacoeconomics Society, ISPOR Poland 2010, December 2, 2010, Sobieski Hotel, Warsaw, Poland.)

Lee LJ, Klein RW, Klein TM, Furiak N, Peltz G, Bansal M, Jackson JA, Juneja R. Evaluation of cost and clinical outcomes by HbA1c at diagnosis using various diabetes treatment strategies. Value Health. 2010;13(7):A289. (Poster PDB33 ISPOR 13th Annual European Congress, Prague, Czech Republic, Nov 17, 2010).

Smolen LJ, Gregor Z, Barrett A, Myren KJ, Toll A. Cost-effectiveness of teriparatide in patients with glucocorticoid-induced osteoporosis in Sweden. Value Health. 2010;13(7):A308. (Poster PMS35 ISPOR 13th Annual European Congress, Prague, Czech Republic, Nov 17, 2010).

Olsson AG, Jensen MM, Gandhi SK, Smolen L, Paulsson T. The cost-effectiveness of rosuvastatin versus simvastatin for the prevention of cardiovascular morbidity and mortality in patients with high baseline risk-a Swedish economic evaluation based upon the JUPITER trial. Value Health. 2010;13(7):A358. (Poster PCV90 ISPOR 13th Annual European Congress, Prague, Czech Republic, Nov 17, 2010).

Smolen LJ, Foster SA, Whiteman D, Lee JL. Comparison of 3mL versus 10mL insulin vial size on hospital pharmacy budget. (Poster SMOL1037H International Hospital Diabetes Meeting, San Diego CA October 8, 2010).

Smolen LJ, Klein RW. Synchronization of random number streams greatly enhances efficiency of probabilistic models. Value Health. 2010;13(3):A16. (Poster PMC15 ISPOR 15th Annual International Meeting, Atlanta, GA, May 17, 2010).

Klein RW, Lawson AH, Muehlenbein CE, Liepa AM, Wielage RC, Babineaux S, Koustenis A. The budgetary impact of pemetrexed maintenance therapy for advanced nonsquamous non-small cell lung cancer. Value Health. 2010;13(3):A28. (Poster PCN25 ISPOR 15th Annual Meeting, Atlanta GA, May 2010).

Furiak NM, Bansal M. The estimated cost-savings of stratified care for migraine headaches from a U.S. perspective. Value Health. 2010;13(3):A138. (Poster PND6 ISPOR 15th Annual Meeting, Atlanta, GA May 2010).

Ohsfeldt R, Gandhi SK, Jensen MM, Smolen L, Fox KM, Hsia J, Gold A. Cost-effectiveness of rosuvastatin 20 mg in secondary-prevention patients in the United States. Value Health. 2010;13(3):A162. (Poster PCV70 ISPOR 15th Annual International Meeting , Atlanta, GA, May 19, 2010).

Ohsfeldt R, Gandhi SK, Jensen MM, Smolen L, Fox KM, Gold A, Hsia J. Cost-effectiveness of rosuvastatin 10 mg in the reduction of cardiovascular morbidity in patients at risk of cardiovascular disease. Value Health. 2010;13(3):A165. (Poster PCV84 ISPOR 15th Annual International Meeting , Atlanta, GA, May 19, 2010).

Smolen H, Klein R, Myers J. Accounting for trial-excluded medical conditions when simulating mortality in clinical trial populations. Value Health. 2010;13(3):A179 (Poster PCV157 ISPOR 15th Annual International Meeting, Atlanta, GA, May 19, 2010).

Klein RW, Lawson AH, Muehlenbein CE, Liepa AM, Wielage RC, Babineaux S, Koustenis A. Budgetary impact of pemetrexed as maintenance therapy for advanced non-small cell lung cancer. (Poster PRR22 Academy of Managed Care Pharmacy April 9, 2010).

Smolen HJ, Klein TM, Klein RW, Cohen DJ. Determining a model-derived relative stroke riskthreshold to justify carotid stenting in surgical high-risk patients. Value Health. 2009;12(7):A320. (Poster PCV45 ISPOR 12th Annual European Congress, Paris France Oct 24, 2009).

Klein R, Muehlenbein C, Wielage R, Liepa A, Babineaux S, Schwartzberg L. The importance of histology in evaluating the cost-effectiveness of pemetrexed maintenance after first-line therapy for advanced non-small cell lung cancer. (Poster 31st Annual Meeting of the Society for Medical Decision Making, Hollywood, CA, Oct 20, 2009).

Kahle-Wrobleski K, Klein R, Furiak N, Siemers E, Klein T. Biomarker screening for Alzheimer’s Disease: when to screen and how often? (ICAD July 2009)(IHIF Neuroscience December 2009)(NCDEU May 2010).

Ascher-Svanum H, Furiak NM, Klein RW, Montgomery W, Smolen LJ, Lawson AH, Conley RR. Cost-effectiveness of olanzipine long-acting injection in the treatment of non-adherence patients with schizophrenia in the United States. Value Health. 2009;12(3):A176. (Poster PMH21 ISPOR 14th Annual International Meeting, Orlando FL, May, 2009).

Muehlenbein C, Wielage R, Liepa A, Babineaux S, Klein R, Schwartzberg L. The budgetary impact of pemetrexed plus cisplatin as first-line therapy for advanced nonsquamous non-small cell lung cancer. Value Health. 2009;12(3):A39. (Poster PCN20 ISPOR 14th Annual International Meeting, Orlando FL, May, 2009).

Klein TM, Wielage RC, Furiak NM, Klein RW. Using an encounter-based database to validate a disease progression model: Lessons for modelers. Value Health. 2009;12(3):A25. (Poster PMC30 ISPOR 14th Annual International Meeting, Orlando FL, May, 2009).

Kahle-Wrobleski K, Siemers ER, Sarpong E, Furiak N, Klein T, Klein R, Callahan C. Biomarker screening for Alzheimer’s Disease: Sensitivity and specificity parameters (AAN).

Smolen HJ, Einterz RM. A simulation-based approach to modeling the effects of intervention strategies on the spread of meningococcal meningitis. Value Health. 2008;11(6):A428. (Poster PIN3 ISPOR 11th Annual European Congress, Athens Greece Nov 2008).

Furiak NM, Kahle-Wrobleski K, Siemers ER, Klein TM, Sarpong E, Klein RW. Modeling screening and prevention of Alzheimer’s Disease. (Poster 30th Annual Meeting of the Society for Medical Decision Making, Philadelphia PA, Oct 20, 2008).

Ascher-Svanum H, Furiak NM, Klein RW, Smolen LJ, Watson, P. Cost-effectiveness of orally dissolving olanzipine tablets in the treatment of schizophrenia in the USA. Value Health. 2008;11(3):A121. (Poster PMH35 ISPOR 13th Annual International Meeting, Toronto CA, May, 2008).

Kessler WR, Klein RW, Wielage RC, Rex DK. Cost savings of removing diminutive polyps without laboratory histology. American Public Health Association. 136th Annual Meeting; San Diego CA; 2008.

Kessler WR, Klein RW, Wielage RC, Rex DK. Cost savings of removing diminutive polyps without histological assessment. Gastrointest Endosc. 2008;67(5):AB105.

Ascher-Svanum H, Furiak NM, Klein RW, Smolen LJ, Zhu B. Cost-effectiveness of olanzapine versus generic risperidone and other antipsychotics in standard oral formulations in patients with schizphrenia in the US. Value Health. 2007;10(6):A294. (Poster PMH23 ISPOR 10th Annual European Congress, Dublin Ireland, Oct 21, 2007).

Klein RW, Yaesoubi R, Roberts SD. Factor screening for parsimony of variables in pharmacoeconomic models. Value Health. 2007;10(3):A55. (Poster PCV62 ISPOR 12th Annual International Meeting, Arlington VA, May 21, 2007).

Yaesoubi R, Roberts SD, Klein RW, Chalasani NP, Imperiale TF. Factor screening to identify factors which influence strategy selection. (Poster III-2 28th Annual Meeting of the Society for Medical Decision Making, Cambridge MA, October 17, 2006).

Klein RW, Imperiale TF, Chalasani N. A cost effectiveness analysis of screening for esophageal varices: how good does a clinical decision aid have to be? Value Health. 2006;9(3):A45. (Poster PG18 ISPOR 11th Annual International Meeting, Philadelphia PA, May 22, 2006).

Thomas NA, Zhu B, Ascher-Svanum H, Faries D, Montgomery W, Furiak NM. Adherence levels and differential use of mental health services in the treatment of schizophrenia. Value Health. 2006;9(3):A76. (Poster PMH38 ISPOR 11th Annual International Meeting, Philadelphia PA, May, 2006).

Imperiale TF, Klein RW, Chalasani N. A cost-effectiveness and cost-utility analysis of variceal ligation versus beta-blockers for primary prophylaxis of variceal bleeding. Gastroenterology. 2006;130 (4):A810.

Russell JM, Furiak N, Klein R, Yurgin N, Marciniak M, Bowman L. Using a generalized anxiety disorder disease state model to quantify the effects of effective diagnosis and treatment on overall remission rates. Eur Neuropsychopharmacol. 2005,15(S3):S553.

Klein RW, Ohsfeldt RL, Smolen LJ, McCollam PL. Potential 30-day cost savings from acute coronary syndrome treatment improvements. American College Clinical Pharmacists, San Francisco, May 2005.

Rousculp MD, Klein RW, Smolen LJ, Ohsfeldt RL, Johnston JA. Cost-effectiveness of pharmacological treatment in postmenopausal women. Med Decis Making. 2005. (Poster I-11 SMDM 28th Annual Meeting, San Francisco CA, October, 2005).

Klein RW, Ohsfeldt RL, Smolen LJ, McCollam PL. Potential cost savings from acute coronary syndrome treatment improvements. Value Health. 2005;8(3):262. (Poster PCV5 ISPOR 10th Annual International Meeting, Washington DC, May, 2005).

Smolen HJ, Ohsfeldt RL, Klein RW, Poret AW, Weinberger MH. An ARB cost-effectiveness model treating mild-to-moderate hypertension. Value Health. 2004;7(3): 26. (Poster PCV28 ISPOR 9th Annual International Meeting, Arlington VA, May, 2004).

Ness RM, Klein RW, Wang L, Dittus RS. The cost-effectiveness of fecal DNA testing for colorectal cancer. Gastroenterol. 2003; 124:A234.

Ohsfeldt RL, Kreder KJ, Klein R, Chrischilles EC. Cost-effectiveness of tamsulosin, doxazosin, and terazosin in the treatment of benign prostatic hyperplasia. Value Health. 2003;6(3):288. (Poster PRK9 ISPOR 8th Annual International Meeting, Arlington VA, May, 2003).

Imperiale TF, Chalasani N, Klein RW. Cost-effectiveness analysis of measuring hemodynamic response to primary pharmacoprophylaxis for variceal bleeding. Med Decis Making. 2001;21(6):528.

Ness RM, Klein RW, Holmes AM, Dittus RS. Is an increased frequency of post-polypectomy surveillance cost-effective in patients with a family history of colorectal cancer? Gastroenterology. 2000; 118:A265.

Ness RM, Klein RW, Holmes AM, Dittus RS. Is an increased frequency of rescreening cost-effective in patients with a family history of colorectal cancer? Gastroenterology. 2000;118:A264.

Ness RM, Klein RW, Holmes AM, Dittus RS. What is the cost-utility of post-polypectomy colonoscopy surveillance strategies in persons with a family history of colorectal cancer? Med Decis Making. 1999,19(4):527.

Ness RM, Klein RW, Holmes AM, Dittus RS. What is the cost-utility of colonscopic re-screening in persons with a family history of colorectal cancer but no adenoma on initial screening? Med Decis Making. 1999,19(4):544.

Ness RM, Klein RW, Holmes AM, Dittus RS. Is rescreening cost-effective when no polyps are found at initial screening? Gastroenterology. 1999;116:A84.

Ness RM, Klein RW, Holmes AM, Dittus RS. Is post-polypectomy surveillance cost-effective? Gastroenterology. 1999;116:A84.

Ness RM, Klein RW, Holmes AM, Dittus RS. What is the effect of initial screening age on the cost-effectiveness of post-polypectomy surveillance. Gastroenterology. 1999;116:A84.

 

 

Bold type denotes MDM employee at time of research contribution.